The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

AR-1K2975     N-[(1S)-3-amino-1-[[(1S,2R)- 1-[[(1S)-3...

Synonyms: LS-187214, AC1L2J95
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of colistin

 

High impact information on colistin

 

Chemical compound and disease context of colistin

 

Biological context of colistin

  • These results will be helpful for understanding the pharmacokinetics and pharmacodynamics of colistin and CMS in humans and animals [15].
  • The hydrolysis products were assumed to be a complex mixture of many different sulfomethyl derivatives, including colistin [15].
  • The time-kill kinetics of colistin against A. baumannii ATCC 19606 and clinical isolate 6 were investigated, and population analysis profiles (PAPs) were conducted [5].
  • The third strain (RO180) was resistant primarily to colistin and lacked plasmids [16].
  • Among these clinical strains, four presented resistant phenotypes during successive imipenem and colistin treatments [17].
 

Anatomical context of colistin

 

Associations of colistin with other chemical compounds

 

Gene context of colistin

  • The patient was readmitted to the ICU for a 2nd and a 3rd exacerbation of COPD and was again treated with imipenem and colistin [26].
  • Ten other CF candidates did not use colistin sodium [27].
  • However, only colistin increased HNE activity in sputum (+102%) and was therefore studied in more detail [28].
  • In vivo treatment with free or nanoparticle-bound colistin did not significantly reduce the number of viable Salmonella C53, either in the liver or the spleen of infected mice [29].
  • Susceptibility testing to 12 antibiotics showed that 40 of 69 (58%) non-O1, non-O139 strains were resistant to colistin, streptomycin and sulphisoxazole and 28 of 69 (41%) were multiple antibiotic resistant (MAR; > or = 4 antibiotics) [30].
 

Analytical, diagnostic and therapeutic context of colistin

References

  1. Co-trimoxazole alone for prevention of bacterial infection in patients with acute leukaemia. Starke, I.D., Donnelly, P., Catovsky, D., Darrell, J., Johnson, S.A., Goldman, J.M., Galton, D.A. Lancet (1982) [Pubmed]
  2. Oral antibiotics as a novel therapy for arthritis: evidence for a beneficial effect of intestinal Escherichia coli. Nieuwenhuis, E.E., Visser, M.R., Kavelaars, A., Cobelens, P.M., Fleer, A., Harmsen, W., Verhoef, J., Akkermans, L.M., Heijnen, C.J. Arthritis Rheum. (2000) [Pubmed]
  3. Pseudomonas bacteremia. Review of 108 cases. Flick, M.R., Cluff, L.E. Am. J. Med. (1976) [Pubmed]
  4. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Hamer, D.H. Am. J. Respir. Crit. Care Med. (2000) [Pubmed]
  5. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Li, J., Rayner, C.R., Nation, R.L., Owen, R.J., Spelman, D., Tan, K.E., Liolios, L. Antimicrob. Agents Chemother. (2006) [Pubmed]
  6. Utility of selective digestive decontamination in mechanically ventilated patients. Ferrer, M., Torres, A., González, J., Puig de la Bellacasa, J., el-Ebiary, M., Roca, M., Gatell, J.M., Rodriguez-Roisin, R. Ann. Intern. Med. (1994) [Pubmed]
  7. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Dekker, A.W., Rozenberg-Arska, M., Verhoef, J. Ann. Intern. Med. (1987) [Pubmed]
  8. Antibiotic therapy for chronic infection of pseudomonas in the lung. Høiby, N. Annu. Rev. Med. (1993) [Pubmed]
  9. Polymyxin B is an inhibitor of insulin-induced hypoglycemia in the whole animal model. Studies on the mode of inhibitory action. Amir, S., Sasson, S., Kaiser, N., Meyerovitch, J., Shechter, Y. J. Biol. Chem. (1987) [Pubmed]
  10. Alanine esters of enterococcal lipoteichoic acid play a role in biofilm formation and resistance to antimicrobial peptides. Fabretti, F., Theilacker, C., Baldassarri, L., Kaczynski, Z., Kropec, A., Holst, O., Huebner, J. Infect. Immun. (2006) [Pubmed]
  11. Effect of a selective decontamination of the digestive tract regimen including parenteral cefepime on establishment of intestinal colonization with vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in mice. Paterson, D.L., Stiefel, U., Donskey, C.J. Antimicrob. Agents Chemother. (2006) [Pubmed]
  12. Microbiological assay for vitamin B12 with use of a colistin-sulfate-resistant organism. Kelleher, B.P., Walshe, K.G., Scott, J.M., O'Broin, S.D. Clin. Chem. (1987) [Pubmed]
  13. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Warren, H.S., Kania, S.A., Siber, G.R. Antimicrob. Agents Chemother. (1985) [Pubmed]
  14. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Zhanel, G.G., Mayer, M., Laing, N., Adam, H.J. Antimicrob. Agents Chemother. (2006) [Pubmed]
  15. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Li, J., Milne, R.W., Nation, R.L., Turnidge, J.D., Coulthard, K. Antimicrob. Agents Chemother. (2003) [Pubmed]
  16. Analysis of increasing antibiotic resistance of Klebsiella pneumoniae relative to changes in chemotherapy. O'Callaghan, R.J., Rousset, K.M., Harkess, N.K., Murray, M.L., Lewis, A.C., Williams, W.L. J. Infect. Dis. (1978) [Pubmed]
  17. Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient. Thiolas, A., Bollet, C., La Scola, B., Raoult, D., Pagès, J.M. Antimicrob. Agents Chemother. (2005) [Pubmed]
  18. A comparison of serum bactericidal activity and phenotypic characteristics of bacteremic, pneumonia-causing strains, and colonizing strains of Branhamella catarrhalis. Jordan, K.L., Berk, S.H., Berk, S.L. Am. J. Med. (1990) [Pubmed]
  19. Antibacterial action of colistin (polymyxin E) against Mycobacterium aurum. David, H.L., Rastogi, N. Antimicrob. Agents Chemother. (1985) [Pubmed]
  20. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. Ratjen, F., Rietschel, E., Kasel, D., Schwiertz, R., Starke, K., Beier, H., van Koningsbruggen, S., Grasemann, H. J. Antimicrob. Chemother. (2006) [Pubmed]
  21. Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin. Katragkou, A., Roilides, E. J. Clin. Microbiol. (2005) [Pubmed]
  22. Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. Koeman, M., van der Ven, A.J., Hak, E., Joore, H.C., Kaasjager, K., de Smet, A.G., Ramsay, G., Dormans, T.P., Aarts, L.P., de Bel, E.E., Hustinx, W.N., van der Tweel, I., Hoepelman, A.M., Bonten, M.J. Am. J. Respir. Crit. Care Med. (2006) [Pubmed]
  23. Minimum antibiotic levels for selecting a resistance plasmid in a gnotobiotic animal model. Corpet, D.E., Lumeau, S., Corpet, F. Antimicrob. Agents Chemother. (1989) [Pubmed]
  24. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Li, J., Milne, R.W., Nation, R.L., Turnidge, J.D., Smeaton, T.C., Coulthard, K. Antimicrob. Agents Chemother. (2003) [Pubmed]
  25. Activity of Cecropin A-Melittin Hybrid Peptides against Colistin-Resistant Clinical Strains of Acinetobacter baumannii: Molecular Basis for the Differential Mechanisms of Action. Saugar, J.M., Rodríguez-Hernández, M.J., de la Torre, B.G., Pachón-Ibañez, M.E., Fernández-Reyes, M., Andreu, D., Pachón, J., Rivas, L. Antimicrob. Agents Chemother. (2006) [Pubmed]
  26. Suspected acute interstitial nephritis induced by colistin. Kallel, H., Hamida, C.B., Ksibi, H., Bahloul, M., Hergafi, L., Chaari, A., Chelly, H., Bouaziz, M. J. Nephrol. (2005) [Pubmed]
  27. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation. Bauldoff, G.S., Nunley, D.R., Manzetti, J.D., Dauber, J.H., Keenan, R.J. Transplantation (1997) [Pubmed]
  28. Colistin stimulates the activity of neutrophil elastase and Pseudomonas aeruginosa elastase. Jones, A., Elphick, H., Pettitt, E., Everard, M.L., Evans, G.S. Eur. Respir. J. (2002) [Pubmed]
  29. Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Page-Clisson, M.E., Pinto-Alphandary, H., Chachaty, E., Couvreur, P., Andremont, A. Pharm. Res. (1998) [Pubmed]
  30. A high proportion of Vibrio cholerae strains isolated from children with diarrhoea in Bangkok, Thailand are multiple antibiotic resistant and belong to heterogenous non-O1, non-O139 O-serotypes. Dalsgaard, A., Forslund, A., Bodhidatta, L., Serichantalergs, O., Pitarangsi, C., Pang, L., Shimada, T., Echeverria, P. Epidemiol. Infect. (1999) [Pubmed]
  31. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Kasiakou, S.K., Michalopoulos, A., Soteriades, E.S., Samonis, G., Sermaides, G.J., Falagas, M.E. Antimicrob. Agents Chemother. (2005) [Pubmed]
 
WikiGenes - Universities